Other formats:
BibTeX
LaTeX
RIS
@article{1398972,
author = {Prochazka, V. and Papajik, T. and Janíková, Andrea and Belada, D. and Kozak, T. and Šálek, David and Sykorova, A. and Mocikova, H. and Campr, V. and Dlouha, J. and Langova, K. and Furst, T. and Trneny, M.},
article_location = {LONDON},
article_number = {3},
doi = {http://dx.doi.org/10.1080/10428194.2016.1213834},
keywords = {Autologous transplantation; chemotherapy; follicular lymphoma; prognosis},
language = {eng},
issn = {1042-8194},
journal = {LEUKEMIA & LYMPHOMA},
title = {Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database},
url = {http://dx.doi.org/10.1080/10428194.2016.1213834},
volume = {58},
year = {2017}
}
TY - JOUR
ID - 1398972
AU - Prochazka, V. - Papajik, T. - Janíková, Andrea - Belada, D. - Kozak, T. - Šálek, David - Sykorova, A. - Mocikova, H. - Campr, V. - Dlouha, J. - Langova, K. - Furst, T. - Trneny, M.
PY - 2017
TI - Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database
JF - LEUKEMIA & LYMPHOMA
VL - 58
IS - 3
SP - 601-613
EP - 601-613
PB - INFORMA HEALTHCARE
SN - 10428194
KW - Autologous transplantation
KW - chemotherapy
KW - follicular lymphoma
KW - prognosis
UR - http://dx.doi.org/10.1080/10428194.2016.1213834
L2 - http://dx.doi.org/10.1080/10428194.2016.1213834
N2 - Optimal frontline treatment in younger high tumor-burden risk follicular lymphoma patients remains a challenge given the reduced efficacy of standard immunochemotherapy (R-CHOP) in widespread disease and unclear role of intensive induction. The retrospective non-randomized pair-matched (1: 3) analysis compared 48 intermediate/ high Follicular Lymphoma International Prognostic Index (FLIPI) patients receiving intensive rituximab sequential chemotherapy (R-SQ) with 144 random controls (R-CHOP) matched for age, FLIPI score, and maintenance delivery. Complete response rates were 91.7% and 74.1%, respectively (p = .038). After a median followup of 8.8 (R-SQ) and 6.5 years (R-CHOP), 5-year time to treatment failure, progression-free survival, and overall survival were 80.9%, 83.2%, and 100% and 57.5%, 60.3%, and 92.1% (p = .0044; p = .0047; p = .22), respectively. Intensive treatment was accompanied by higher acute hematologic toxicity and infections, comparable non-hematologic toxicity, and incidence of secondary malignancies. Intensive induction demonstrates superior long-term disease control compared to R-CHOP, with higher acute hematologic toxicity, but without acute treatment-related mortality. Further studies are needed to define ultra-high-risk FL patients benefiting most from treatment intensity.
ER -
PROCHAZKA, V., T. PAPAJIK, Andrea JANÍKOVÁ, D. BELADA, T. KOZAK, David ŠÁLEK, A. SYKOROVA, H. MOCIKOVA, V. CAMPR, J. DLOUHA, K. LANGOVA, T. FURST and M. TRNENY. Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database. \textit{LEUKEMIA \&{}amp; LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2017, vol.~58, No~3, p.~601-613. ISSN~1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2016.1213834.
|
